QualityStocks.net News – SGX Pharmaceuticals, Inc. (SGXP) Submits FDA Investigational New Drug Application

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight SGX Pharmaceuticals, Inc. (NASDAQ: SGXP). The company is a biotechnology company focused on the discovery, development and commercialization of targeted therapeutics directed at addressing unmet medical needs in oncology. The Company's most advanced drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers, and the BCR-ABL tyrosine kinase enzyme, for treatment of Chronic Myelogenous Leukemia (CML), a cancer of the bone marrow.

In the company’s recent news,

SGX Pharmaceuticals announced its submission of an Investigational New Drug (IND) application for FDA approval. The drug is known as SGX393, and is currently undergoing clinical testing of its ability to treat two forms of CML, or, chronic myelogenous leukemia (a type of cancer in which white blood cells belonging to the myeloid line of cells are over-produced in the bone marrow). At present, the standard treatment for CML is a product known as Gleevec®, however there have been several cases where candidates have either relapsed, or been unresponsive or intolerant of the drug.

The majority of relapses have occurred as a result of several mutated forms of the tyrosine kinase BCR-ABL. The mutation that has caused the most trouble is known as the T315I mutant, and neither Gleevec®, nor the next two most popular CML treatments (Sprycel® and Tasigna®), have been successful in inhibiting the anomaly. SGX393 does inhibit the T315I mutant and several other drug-resistant forms of BCR-ABL. If approved by the FDA, SGX Pharmaceuticals’ SGX393 could become the preferred method of CML treatment.

Mike Grey, CEO of SGX Pharmaceuticals stated: “Filing of this IND submission represents another testament to our internal capabilities. We continue to focus on moving our discovery and development programs forward.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.